Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377979 | 1.00 | ESR1 (0.52) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL6375768 | 1.00 | ESR1 (0.52) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL27527326 | 0.94 | ESR1 (0.47) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL5898775 | 0.88 | ESR1 (0.46) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL5898772 | 0.88 | ESR1 (0.46) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL27314214 | 0.88 | ESR1 (0.42) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL28478636 | 0.87 | ESR1 (0.52) | ESR1ESR2KIF11LMNAMAPK1 | |
| Water SCHEMBL28060764 | 0.86 | ESR1 (0.41) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL5898746 | 0.85 | LMNA (0.56) | ESR1ESR2KIF11LMNAMAPK1 | |
| SCHEMBL5898749 | 0.85 | LMNA (0.56) | ESR1ESR2KIF11LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1266115-C | Process for the preparation of 2- (2-arylmorpholin-2-yl) -ethanol and intermediates | SANOFI SYNTHELABO (FR) | 2006-07-26 | — | — | CN | disclosed |
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-03 | — | — | US | disclosed |
| CN-1183121-C | Process for the preparation of 2- (2-arylmorpholin-2-yl) -ethanol and intermediates | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2005-01-05 | — | — | CN | disclosed |
| CN-1534015-A | Preparation method of 2-(2-arylmorpholine-2-yl)-ethanol and intermediate | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-10-06 | — | — | CN | disclosed |
| CN-1367781-A | Process for the preparation of 2- (2-arylmorpholin-2-yl) -ethanol and intermediates | SANOFI SYNTHELABO (FR) | 2002-09-04 | — | — | CN | disclosed |
| EP-1063888-A1 | NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS | The Regents of the University of California (US) | 2001-01-03 | — | — | EP | disclosed |
| CN-1052231-C | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2000-05-10 | — | — | CN | disclosed |
| WO-1999048371-A1 | NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-30 | — | — | WO | disclosed |
| CN-1097421-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1995-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | DDO, DNTT, DSTYK | ESR1 1701/4885ESR2 4087/4885KIF11 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.